Psoriasis Patients Experience High Rates of Cardiometabolic Comorbidities

Cardiometabolic comorbidity rates are high among patients with psoriasis, according to a recent study.

In their study, researchers analyzed the prevalence and incidence of 24 comorbidities using commercial claims from 469,097 patients who submitted 2 or more health claims for psoriasis between July 1, 2008 and June 20, 2014.
__________________________________________________________________________________________________________________________
RELATED CONTENT
Weight Loss Reduces Severity of Psoriasis
Depression Increases Risk for Psoriatic Arthritis in Patients with Psoriasis
__________________________________________________________________________________________________________________________

Hyperlipidemia, hypertension, depression, type 2 diabetes, and obesity were the most common comorbidities identified in patients with psoriasis. The prevalence and incidence was 45.64% and 30.83% for hyperlipidemia, respectively, 42.19% and 24.19% for hypertension, respectively, 17.91% and 12.68% for depression, respectively, 17.45% and 8.44% for diabetes, respectively, and 14.38% and 11.57% for obesity, respectively.

“Comorbidity rates align with those described in the literature and support the concept that psoriasis patients have high rates of cardiometabolic comorbidities,” the researchers concluded. “This analysis highlights the potential utility of very large insurance databases for determining comorbidity prevalence in psoriasis, which may aid health care providers in managing psoriasis.”

—Melissa Weiss

Reference:

Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis [published online June 13, 2017]. J Am Acad Dermatol. http://dx.doi.org/10.1016/j.jaad.2017.03.037.